Nektar Therapeutics' Phase 2b REZOLVE-AD Study Meets Primary Goal
(RTTNews) - Nektar Therapeutics (NKTR) Tuesday reported positive data from Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with atopic dermatitis. The study met its primary goal.
The study achieved statistical significance on primary endpoint of mean improvement in Eczema Area and Severity Score (EASI) from baseline versus placebo at week 16.
The company expects to report data from the continued treatment of patients with atopic dermatitis in long-term maintenance part of REZOLVE-AD study in the first quarter of 2026.
Data from Phase 2b study of rezpegaldesleukin in alopecia areata is expected in the fourth quarter of 2025.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.